Millipore hopes its $23m (€18m) swoop for Guava Technologies will draw attention away from the underperformance of its bioprocess division, revenue from which fell 6 per cent in Q4 to $214m (€165m) and 2 per cent for 2008 overall.
The lacklustre performance of Millipore’s bioprocess division has continued into the second quarter of the year with revenues reaching $229.8m (€147m) up just one per cent on the comparable 2007 quarter.
Danish diabetes care specialist Novo Nordisk has expanded an
agreement with biotech supplier Millipore, granting exclusive,
long-term distribution rights to the company's insulin
products for cell culture applications.
One-off costs related to last year's acquisition of Serologicals
and a continuing manufacturing consolidation strategy were largely
responsible for sharp falls in Millipore's pre-tax and net profits
for the first quarter...
US-based biopharmaceutical product providers Millipore has met its
revenue and earnings target over the fiscal year, helped by its
Serologicals acquisition in the fourth quarter and a solid
performance by its main business driver:...
Millipore has introduced a new disposable product - NovaSeal - that
ties in with a shift in the bioprocess manufacturing market to the
use of disposable assemblies to shorten production cycles for